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,.,., C.,,p ,d Analysis of carcinogenicity and genetic
toxicity data for chemicals subjected to
the National Toxicology Program (NTP)
bioassay for carcinogenicity have demon-
strated that nearly 40% of the chemicals
ee---°ac~*ens~#~ 3 that were positive in the bioassay were
negative in tests for genetic toxicity (1).
rThese findings, together with evidence of
-. the role of cell proliferation in chemical
=hich carcinogenesis, provide further evidence
~that receptor-mediated responses may
tnsmo -o~ie responsca -g~ play a critical role in the carcinogenic
actions of many chemicals (2,3). Of par-
"""*:':............'m ed iat ticular interest are those receptor-mediat-
.... '....... . ... ed events that trigger mitogenic responses
in normal and genetically altered cells.
°,a°,i,nop'eci ,.y i° ''''' %c There is increasing controversy re-
garding risk assessment procedures for
chemical carcinogens. At the forefront of
CDpp-glk this controversy is the issue of the appro-
2 i{ horinie - priateness of linear models or safety fac-
tor approaches
for estimating human
nasesssnenisffi-tC. - -. risks. The linear multistage model is
-commonly used by regulatory agencies,
and it assumes that the risk is proportion-
pape. we °he ately related to dose/exposure level in the
low-dose region of the dose-response
e&_ - curve. In contrast, safety factor models
assume that there is an exposure level
aiis aia,glebelow which no adverse effect can occur.
o_he tLSisEPAis cserentli' weerahiameg.'.d There is little disagreement over the use
risks_ of the linear multistage model for car-
biOl#alue0ti4slLhe cinogens that appear to act by damaging
- id s,_sS,s,s,s,s _le DNA in such a way that somatic muta-
r-isto° tions are produced. The assumption is
that one genetically altered cell can even-
tually lead to cancer, although it is now
thiwe'.a clearly recognized that cancer is a multi-
*!.] o, .....- .. ......
Ea,,,0 p1( roundsstage pro-cess involving several mutations
and multiple mechanisms governing
selective growth of these genetically
altered cells (2,1').
The risk assessment controversy sur-
ds policies for assessin risks of the
so-called nongenotoxic carcinogens: those
substances that do not produce somatic
.....
mutations but instead increase the
growth rates of normal and/or abnormal
~~~~~~cells, thereby increasing risks of tumor
................... development. One opinion is that this
class of carcinogens should exhibit a
threshold and that a safety factor ap-
proach is the most appropriate for esti-
mating human risks. Others argue that
the group of chemicals that make up the
class of non-genotoxic carcinogens act by
several different mechanisms, and it is
misleading and scientifically incorrect to
treat all nongenotoxic chemicals the same
for risk assessment purposes. For exam-
ple, one chemical might stimulate mitotic
activity by modifying receptor-mediated
signal transduction pathways, whereas
another chemical might also stimulate
cell division but by a compensatory
mechanism linked to cytolethality (5). It
is likely that dose-response relationships
for these two mechanisms will be very
different.
There has been considerable debate
over the relevance ofusing high-dose ani-
mal data to estimate human risks caused
by chronic low-dose exposure. Several
reports have been published on this issue,
so we will not address it here (6-8). In-
stead, we focus on the emerging insights
regarding dose-response relationships for
receptor-mediated events and the applica-
tion of this information to developing
novel mathematical models that provide
the foundation to use receptor mecha-
nisms in risk assessment.
Although the carcinogenic actions of
many chemicals such as estrogens and
phorbol esters are mediated through re-
ceptor mechanisms, the most visible
example of a receptor-mediated carcino-
gen is dioxin. Risk assessments for diox-
in and its structural analogs have created
an unprecedented emotional and eco-
nomic controversy which include the
issues of health effects in Vietnam veter-
ans, fraud, collusion, and overregulation
(9,10). EPA is currently reevaluating
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health risks associated with dioxin expo-
sure, and this decision has spawned
charges of collusion between federal offi-
cials and industry. Here we evaluate the
strength of the scientific foundation on
which the EPA reevaluation is based,
including an examination of mechanisms
of receptor actions and the scientific
issues that affect the development and
use of biologically based risk assessment
models.
Biochemical and Toxic Effects
of Dioxins
2,3,7,8-Tetrachlorodibenzo-p-dioxin
(TCDD) symbolizes the intense controver-
sy surrounding the issue of dose-response
relationships in receptor-mediated carcino-
gens. TCDD is loosely referred to as "diox-
in." Dioxin is prototypical of a large class
of organohalogens including several poly-
chlorinated dibenzodioxins (PCDDs),
polychlorinated dibenzofurans (PCDFs), a
few polychlorinated biphenyls (PCBs), and
other less common contaminants [see
review by Goldstein and Safe (11)]. The
PCDDs and PCDFs are ubiquitous envi-
ronmental contaminants that arise inadver-
tently during the synthesis of other com-
pounds such as the herbicide 2,4,5-
trichlorophenoxyacetic acid, the active
ingredient in Agent Orange, and in other
processes such as bleaching paper and pulp
and incinerating hazardous wastes. Many
ofthe PCDFs and PCDDs are resistant to
degradation in the environment and in
biological systems. For example, the con-
centrations of these compounds are bio-
magnified in aquatic systems, and the
whole-body half-life in humans for TCDD
is in the range of7-11 years (12). Studies
in the early 1970s revealed that TCDD
possesses extraordinary acute toxicity in
experimental animals. For example, the
LD50 is approximately 1 pig/kg in guinea
pigs and 70 pig/kg in rats (13). Later stud-
ies demonstrated that TCDD is a multisite
carcinogen in several experimental animal
models, and it is a carcinogen in both
sexes, in some cases at doses well below the
maximum tolerated dose (14,15). Several
studies in the scientific literature have
evaluated the genetic toxicology ofTCDD.
These studies have been reviewed by Shu
et al. (16), and taken together they indicate
that TCDD is negative in short-term tests
for genetic toxicity and does not appear to
form DNA adducts. However, the possi-
bility remains that TCDD may damage
DNA by indirect mechanisms such as
enhanced production of DNA-reactive
metabolites of other chemicals and/or
endogenous compounds such as estrogens.
A recent report (17) indicated that TCDD
induced neoplastic transformation in im-
mortalized human keratinocytes. In two-
stage models for liver and skin cancer,
TCDD is a potent tumor promoter with
little or no initiating activity (18-20).
However, it must be kept in mind that
promotion is an operational term, and it
does not convey specific information about
mechanism ofaction. The knowledge that
chemicals of diverse structure are tumor
promoters and the identification of some
ofthe discrete steps involved in tumor pro-
motion provide growing evidence that
there are multiple mechanisms responsible
for tumor promotion (4). Reasonable evi-
dence is now available that dioxin is a
human carcinogen at least at high doses
(21).
In addition to TCDD's carcinogenic
actions, it has a number of other toxic
effects such as immunotoxicity, reproduc-
tive deficits, teratogenicity, and endocrine
toxicity (22). There is an emerging consen-
sus that noncancer endpoints need to be
considered in a complete evaluation of
dioxin's effects. This consensus is based on
numerous experimental findings including
the growing evidence that dioxin is a pow-
erful growth dysregulator. We agree with
this consensus and recommend the devel-
opment ofbiologically based models for all
the potential health effects ofdioxin.
Dioxin modulates the activities of a
vast array of biochemical pathways in-
cluding receptors (estrogen, glucocorti-
coid, epidermal growth factor), hor-
mones, components of intermediary me-
tabolism, transforming growth factor,
tumor necrosis factor, metabolic activa-
tion/deactivation mechanisms (cyto-
chrome P450 and uridine diphosphate
glucuronyltransferase isozymes), inflam-
mation factors, interleukins, and proto-
oncogene expression (22-24). Our bur-
geoning knowledge on the wide spectrum
ofgrowth factors and growth factor path-
ways that are modulated or regulated by
dioxin, coupled with recent information
on the capacity of dioxin to enhance cell
proliferation rates, may lead to the identi-
fication ofcritical target genes for dioxin's
effects. However, the ability ofdioxin to
elicit toxic effects most surely requires the
interaction of multiple genes. Further
complexity is added by cell specificity and
hormonal regulation of dioxin's effects.
For example, TCDD is a potent promoter
of liver tumors in intact female rats, and
it also induces significant increases in
mitotic activity of hepatocytes in fe-male
rats (19). However, in ovariectom-ized
rats, TCDD does not induce hepatocyte
proliferation nor liver tumors, but it does
promote lung tumors which are not
observed in intact female rats (25).
Clearly, estrogens play a dominant role in
regulating the site specificity of the
tumorgenicity ofdioxin.
Ah Receptor: Lessons from
Steroid Receptors
Although substantial gaps in our knowl-
edge remain, it is generally agreed that an
early event in most, if not all, of dioxin's
effects.require interaction with a cellular
protein, the Ah receptor (AhR), which was
discovered by Alan Poland in 1976 (26).
The binding ofTCDD to AhR is similar,
although not identical, to the interaction
ofmany steroid hormones with their intra-
cellular receptors. However, steroid hor-
mones do not bind the Ah receptor, and
TCDD does not bind to known steroid
receptors. Moreover, any chemical that
binds to the Ah receptor appears to pro-
duce the same spectrum of biochemical
and toxic effects as dioxin, and the potency
of these responses reflects the binding
affinity ofthat chemical to the Ah receptor
(11). TCDD binds the Ah receptor with
high affinity (Kd approximately 10-10 M),
and the binding is reversible (23,26,24. It
is generally accepted that Ah receptor oc-
cupancy is linearly related to low cellular
concentrations ofdioxin.
There is considerable information
available on the interaction of the TCDD
receptor complex with the cytochrome
P4501AI gene, which is transcriptionally
activated by TCDD and its structural
analogs. Cytochrome P450 is composed of
numerous isozymes, and it functions in the
detoxication and/or metabolic activation of
many chemicals. TCDD induces the syn-
thesis and catalytic activity of CYPIAJ and
CYP1A2. Much of this work is summa-
rized in a recent review (27. Biochemical
studies indicate that the functional form
(liganded) of the receptor is a heteromer
(28), and the functional form ofthe recep-
tor appears to contain a ligand-binding
domain and a DNA-binding domain.
Recently, cDNA cloning approaches have
shown that the ligand-binding component
has a basic helix-loop-helix (bHLH) motif
similar to that for some other transcription
factors (29,30). Moreover, the Arnt (Ah
receptor nuclear translocation) protein
which activates the DNA binding also con-
tains a bHLH motif (31). It is thought
that the common bHLH motifs allow the
Ah receptor and theArnt protein to dimer-
ize, forming the functional DNA binding
complex similar to other bHLH transcrip-
tion factors. Induction of transcription of
the CYPIAI gene requires binding of the
liganded receptor to specific elements in
the gene, which have been termed "dioxin-
responsive elements" or "xenobiotic-
responsive elements" (DRE, XRE). There
are multiple binding sites, and the binding
is reversible. Each receptor binding site
contains a core recognition sequence, and
the liganded receptor appears to bind with-
in the major DNA groove similar to other
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Figure 1. One possible computer-generated
model of the dioxin: Ah receptor: Arnt protein:
DNA complex based on the prior model (48) ofthe
b-HLH (basic region, helix-loop-helix) binding to
DNA (AAACATATGM). Backbone DNA (black),
dioxin (red), and the HLH protein models ofthe Ah
receptor and Arnt protein (blue-green). (We
thank Zelda Wasserman and William Degrado for
sending ustheir model coordinates.)
systems that are regulated by bHLH tran-
scription factors (27,32). It is important
to remember that the molecular character-
istics that regulate induction of CYPlAI
may be different for other dioxin-respon-
sive genes. Figure 1 illustrates DNA inter-
actions for bHLH transcription factors
such as the liganded AhR.
Much of the sequence of molecular
events governing transcriptional activation
of the CYPIAI gene are analogous to
receptor-mediated events for steroid hor-
mones. This similarity helps us in propos-
ing biological models ofTCDD action for
risk assessment purposes. The steroid hor-
mones and their receptors belong to a
multigene family that includes the thyroid
hormone receptors, oncogene products,
glucocorticoids, mineralocorticoids, vita-
min D, retinoids, androgens, estrogens,
and progestins. Biologically, these are all
multipotent agents that induce a range of
cellular responses in different organs,
many at extremely low concentrations.
Within the family of known receptors for
these agents, there is considerable se-
quence homology and a common basic
structure, consisting of a ligand-binding
domain and a DNA-binding domain, as
discussed above for AhR. Some receptors
are associated with so-called heat shock
proteins or proteins that must be shed to
transform the liganded receptor into a
DNA-binding form (33).
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Figure 2. (a) Concentration-dependent hormone response when there is a proportional relationship
among hormone concentration, receptor occupancy, and biologic response. Data are plotted on a semi-
log scale and demonstrate that the entire dose response spans at least six orders of magnitude. (b)
Proportional relationship among hormone concentration, receptor occupancy, and biologic response
using the same data set plotted in panel (a) plotted on an arithmetic scale. In this case, linearity of
response is clearly seen in the low concentration region, followed by saturation atthe higher concentra-
tions.
Dose-Response Relationships
for Receptor-mediated Events
Attempts to mathematically model the
steps involved in signal transduction have
examined events step by step as well as the
overall set of reactions from entrance of
hormone into the cell to cellular response.
Of interest here is the information avail-
able concerning the overall dose-response
relationship for hormones.
Evaluation of dose-response relation-
ships for receptor-mediated events require
information on the quantitative relation-
ships among ligand concentration, receptor
occupancy, and biologic response. Ac-
cording to Roth and Grunfeld (34):
At very low concentrations of hormone
([H]<<Kd), receptor occupancy occurs
but may be trivial; i.e., the curve
approaches 0% occupancy of receptors.
But ifthere are 10,000 receptors per cell
(a reasonable number for most systems),
the absolute number of complexes
formed is respectable even at low hor-
mone concentrations.
Figure 2a illustrates the situation de-
scribed above where there is a proportional
relationship between receptor occupancy
and biological response. In this situation
occupancy of one receptor would produce
a response, although it is unlikely that this
response could be detected. The biological
significance of such a response is likely
negligible, but this is not certain, and it
may vary with endpoint as well as with
developmental stage and cell type. Note
that the data in Figure 2a are plotted on a
semilog scale. Ifthe same data are plotted
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Figure 3. Schematic representation of the com-
plex sequence of molecular and biological events
involved in dioxin-mediated toxicants.
arithmetically (Fig. 2b), the shape of the
dose-response curve readily conveys a lin-
ear relationship between receptor occupan-
cy and biological response at lower concen-
trations and saturation at higher concen-
trations.
Such a simple proportional relationship
does not explain the diversity ofbiological
responses that can be elicited by a single
hormone using a single receptor. For
example, low concentrations of insulin
produce much greater effects on fat cells
than on muscle cells. These differences are
due to tissue- and cell-specific factors that
modulate the qualitative relationship
between receptor occupancy and response.
Similarly, it is expected that there are
markedly different dose-response relation-
ships for different effects of TCDD. Co-
ordinated biological responses, such as
TCDD-mediated increases in cell prolifer-
ation, likely involve other hormone sys-
tems, which means that the dose-response
relationships for effects involving single
genes (i.e., CYPIAI induction) may not
accurately predict dose-response relation-
ships for complex responses such as cancer.
Indeed, recent studies have demonstrated
that there are a wide variety of dose-
response relationships for dioxin's effects
(3,35,36). For example, induction of
CYPIAI and effects on the epidermal
growth factor receptor, within the frame-
work of a two-stage model for dioxin's
hepatocarcinogenic actions, indicate there
is an approximate linear relationship be-
tween target tissue concentration and
response even in the low-dose region.
Curve-fitting approaches (36) as well as
mechanistic models for dioxin-mediated
changes in gene expression (37,38) provide
more evidence for the idea that linear
models for responses in the low-dose
region cannot be rejected simply on the
knowledge that a response is receptor
mediated.
In contrast to dioxin's effects on
CYPlAl and CYP1A2, changes in hepato-
cyte proliferation rates, also within the
framework of a two-stage tumor promo-
tion model, reveal that this endpoint is less
sensitive to dioxin than simple changes in
gene expression (25, R. Maronpot, person-
al communication). Likewise, TCDD-
mediated growth of foci of cellular alter-
ation (preneoplastic lesions) appears to be
less sensitive than enzyme induction. In
contrast, neoplastic transformation of hu-
man keratinocytes occurs at lower concen-
trations than needed to produce detectable
CYPIAI induction (17). These kinds of
data provide striking examples that our
ability to predict dose-response relation-
ships for the effects ofdioxin are limited by
our lack of knowledge on the mechanistic
link between changes in gene expression
and toxic effects. Figure 3 summarizes the
series of interconnected steps within the
three major components ofreceptor-medi-
ated events (recognition, transduction, and
response). Although this scheme is simpli-
fied (i.e., each step may be composed of
several events), it does provide a frame-
work for identifying knowledge gaps that
create uncertainty. Clearly, interactions
with other endocrine systems are involved
in some effects, and our ability to construct
accurate dose-response models for cancer
and noncancer endpoints would be
enhanced ifwe had a better understanding
ofTCDD-endocrine interactions.
In considering possible dose-response
relationships for the effects of dioxin, we
are hampered by our lack of knowledge
concerning the absence or presence of
endogenous ligand(s). We are not certain
if TCDD is more or less stable than this
possible ligand, or if TCDD's affinity is
higher or lower than an endogenous lig-
and. Of course, differences in affinity, if
these exist, may not influence the overall
kinetics of the dose-response relationship
as much as differences in the number of
events required to trigger the reaction from
step to step.
One of the more active areas of re-
search on hormone action is directed at
identifying the cell-specific factors that
produce diversity ofresponses for receptor-
mediated responses; that is, how do a sin-
gle receptor and a single ligand produce
the wide spectrum ofcell-specific responses
characteristic of exposure to a given hor-
mone? Because TCDD is acting like a
potent and persistent hormone agonist/
antagonist, the mechanisms responsible for
qualitative and quantitative differences in
dose-response relationships for Ah recep-
tor-mediated events might be similar to
those mechanisms identified for steroid
hormones. Fuller (39) has summarized
some of the mechanisms responsible for
generating diversity, and these are listed in
Table 1.
Cancer Mechanisms and Risk
Assessment
Cancer is a complex, multistage disease.
Although multiple somatic mutations and
multiple rounds of cell replication are
involved, the sequence ofthose events are far
from clear (3,4). In experimental systems,
initiation is generally thought to be a DNA-
damaging or altering event, and fixation is
the immortalization of the mutation into
Table 1. Mechanisms responsible for generating diversity of steroid hormone responses
Mechanism of diversity
Agonist, antagonist
Receptor gene expression
Activating or inactivating enzymes
Binding proteins (extra- or intracellular)
Cytoplasmic versus nuclear
Isoforms-differential
Splicing
Gene duplication
Hetero- or homodimers
DNA binding factors
Antagonist isoforms
Squelching
Consensus versus nonconsensus
Number of copies
Position
Proximity of other response elements
Gene-specific factors
Cell-specific factors
Componentof receptor action
Ligand
Targettissue
Receptor
Dimers
Nuclearfactors
DNA response elements
Transactivation
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Figure 4. Range of risk assessments made byvarious U.S. regulatory agencies and other countries.
clonally expanded progeny. Promotion is
the enhancement, via modification in cell
growth kinetics, ofthe initiated cell popula-
tion by endogenous and/or exogenous fac-
tors. Progres-sion refers to additional muta-
tions and/or growth ofthe tumor to a clini-
cal end stage. Tumor promotion in experi-
mental animals is an operationally estab-
lished paradigm that has been demonstrated
in many tissues. Dioxin is a promoter in the
skin and liver of experimental animals
(18-20, 40).
The general approach ofthe U.S. EPA
for regulation of carcinogens is to use the
Armitage-Doll model of carcinogenesis.
In this model, the movement ofcells from
one stage to the other is assumed to be due
to a sequence of mutations similar to the
step of initiation/fixation discussed earlier.
As with any mathematical model, specific
forms must be chosen for the rate con-
stants that define the process. The EPA
formulation of this model assumes the
mutation rates are a linear function ofdose
and are constant over time. EPA generally
uses a 95% upper-confidence limit of this
formulation of the multistage model for
cancer risk assessment (41). This model,
using the 95% upper-confidence limit on
the linear term is referred to as the lin-
earized multistage model (LMS). In addi-
tion to chemical carcinogens that increase
mutation rate, the linearized mathematical
properties of the multistage model can be
appropriate for a larger class of mecha-
nisms. In particular, if a compound's
action is additive to background biological
processes, then a linear response is predict-
ed at low doses under rather general condi-
tions (42,43). Therefore, for practical
modeling purposes, it is important to ad-
dress whether biological knowledge and
data on carcinogen action can fit the gen-
eral dose-response shape predicted by the
LMS.
For other toxicological endpoints such
as terata, target organ toxicity, and acute
toxicity, a different approach has been
used. For these endpoints, safety factors or
uncertainty factors have been used to esti-
mate no-effect exposure levels. This ap-
proach is used by the World Health
Organization to set acceptable daily intakes
for direct and indirect food additives. In
contrast, EPA policy assumes the dose-
response curve for excess carcinogenic risk
to be linear through dose zero. As dis-
cussed previously, several mechanisms
could generally lead to this form of
response, including direct mutational
activity ofthe chemical agent and/or addi-
tivity to background rate of tumor forma-
tion. Because TCDD does not bind cova-
lently to DNA and appears to exert its
effects through receptor action, risk assess-
ments for TCDD must be carefully reex-
amined. Countries or agencies that use the
LMS have much higher estimates of risks
than countries that use the safety factor
approach (Fig. 4). For example, EPA,
using the LMS, estimates that a chronic
exposure of 6 fg TCDD/kg day causes an
increased risk of 1 cancer in 1 million peo-
ple exposed to that level. In contrast,
Health and Welfare Canada has estab-
lished a safe exposure level of 10 pg/kg/day
using a safety factor approach (8). Clearly,
Canadians are not 1600 times more sensi-
tive to any adverse health effects of dioxin
than Americans, so these differences in risk
estimates clearly underscore the huge
amount ofuncertainty created by selection
of various risk assessment methodologies.
Although more mechanistically based risk
assessments will still contain significant
uncertainty, we believe that they constitute
an improvement over existing default
approaches. As previously stated by
Greenlee and collaborators (44):
Neither the position taken by U.S. EPA
or by Environment Canada (and several
other countries such as Germany and the
Netherlands) is based on any detailed
mechanistic understanding of receptor-
mediated interactions between dioxin
and target tissues. Biologically based
strategies use knowledge of the mecha-
nistic events in the various steps in the
scheme for risk assessment. Interspecies
extrapolation strategies should be con-
ducted based on how these mechanistic
steps vary from species to species. There
are numerous steps that can be examined
mechanistically, and fairly ambitious
programs have been proposed to exam-
ine the mechanistic details of many or
most ofthese individual steps.
There are a number of issues that must
be considered in the use of biologically
based models to estimate dioxin's risks.
One complicating factor is that exposure
data in humans indicate that the general
population has a body burden TCDD in
the range of 5-10 ppt lipid adjusted (45).
The relationship of this body burden to
enhanced risk of disease, if any, is not
known, although it does appear that enzyme
induction is likely to occur by this exposure
level (35,36). In any event, we need to gain
a clearer understanding of the molecu-
lar/toxicological consequences of back-
ground exposure to TCDD and its structur-
al analogs and dose-response relationships
for incremental increases in exposure. Two
other factors affect our ability to understand
and reduce background exposures of the
human population. First, it is estimated
that the background exposure to TCDD is
0.3 pg/kg/day based on current body bur-
dens, but we do not know all the sources
that are responsible for this body burden.
This information, coupled with the biologi-
cal and ecological persistence of TCDD,
may make it difficult to significantly reduce
current human body burdens of TCDD.
Second, TCDD is prototypical for a broad
class ofchemicals that bind the Ah receptor
(11), so we need to obtain more accurate
estimates of the total exposure to TCDD-
like compounds and ofthe biological poten-
cy of those compounds. Although dose-
response relationships for enzyme induction
appear to be similar between rodents and
humans (46,47), TCDD-mediated human
disease may exhibit dose-response relation-
ships different from enzyme induction. In
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Figure 5. Developing a mechanistically based
mathematical model.
addition, the role of natural ligands has to
be addressed.
The current effort by the EPA to re-
evaluate the risk of exposure to dioxins is
being called a "biological basis for risk
assessment." The underlying premise is
that dioxins may be a special case for non-
mutagenic, receptor-mediated carcinogens.
The goal ofthis reassessment is to consider
more mechanistically based models that are
sufficiently credible to the scientific com-
munity.
As discussed earlier, several important
factors have been generally accepted. First,
TCDD is a member of a class of xenobi-
otics (and probably natural products) that
is nonmutagenic, binds to a cellular recep-
tor, and alters cell growth and develop-
ment. Second, a significant amount ofin-
formation is available for developing
approaches to estimate risks from exposure
to this compound, and the default position
ofdirectly applying the LMS as a function
ofdose needs to be reevaluated. Third, the
biology ofreceptor-mediated events should
be included in any modeling for TCDD.
The goal of mechanistic modeling should
be to use as much data as possible to
reduce these uncertainties and to identify
the areas where data gaps exist.
One difficulty with a novel, albeit bio-
logically based, approach is that it is replac-
ing paradigms (safety factors and LMS
models) upon which the U.S. govern-
ment's risk assessments have been based.
There is no apriori reason to believe that
a model based on greater experimental evi-
dence will be more or less conservative
than the LMS model. However, basing
the modeling on a mechanistic under-
standing of the biochemistry of TCDD-
induced toxicity should increase our confi-
dence in the resulting risk estimates.
Considerations for Modeling
for TCDD
Because there appears to be a strong scien-
tific justification for reevaluating dioxin's
risks, we believe that it is appropriate to
review strategies and approaches for devel-
oping biologically based dose-response
models for dioxin. These models provide
the scientific foundation for the reevalua-
tion. Mathematical modeling can be a
powerful tool for understanding and com-
bining information on complex biological
phenomena. The development and use of
mechanistically based mathematical mod-
els is best described by cycles which are
illustrated by Figure 5. The beginning
point is generally a series of experiments
studying a xenobiotic agent. The experi-
mental results (data) can indicate a mecha-
nism, which leads to the creation ofa ma-
thematical model. The model is used to
make inferences, which are then validated
against the existing knowledge ofthe effect
and the xenobiotic agent being studied.
This process can then lead to new experi-
ments and further laps through this model
development loop. On each pass through
the loop, the model either gains additional
validation by predicting the new experi-
mental results, or it is modified to encom-
pass new results without sacrificing its base
in previous results. In either case, subse-
quent loops through the model generally
increase our confidence in accepting (or
rejecting) a final model. However, it may
be difficult or impossible to quantify this
confidence using a statistical measure.
Confidence in any one model not only
depends on the information available for
that compound, but it is also supported by
the information available on other systems
that act similarly and for which models
have already been developed. In the case
of TCDD, the modeling effort is greatly
enhanced by existing information on the
receptor-based system, general work in
physiologically based pharmacokinetic
models, and tumor incidence modeling.
There is no one model development
loop for any given compound or effect.
Instead, there are numerous pathways lead-
ing to the development of a mechanistic
model. In most comprehensive modeling,
there are many smaller model development
"circuits" that make up the larger, overall
model. For example, a mechanistic
approach to TCDD-induced carcinogenic-
ity must include models ofexposure, tissue
distribution, tissue diffusion, cellular bio-
chemistry, cellular action, tumor inci-
dence, and cancer mortality. At each stage
and for each model, data must be collected
and understood for the model to be valid
and acceptable as a tool for understanding
the observed effects and for predicting the
effects of TCDD outside of the relatively
limited range ofexperimental findings.
The use ofmechanistically based mod-
eling to extrapolate risks of exposure pat-
terns and doses outside the range of the
data is in its infancy. Even though there
may be much confidence in the ability of
the model to predict experimental results,
Table 2. Examples of levels of information avail-
able for estimating parameters in dose-response
modeling.
Level Parameter
Organism Morbidity
Mortality
Fertility
Improper development function
Tissue Hyperplasia
Hypertrophy
Tumorigenesis
Chemical distribution disposition
Cell Mitosis
Cell death
Cytoarchitectural pathology
Biochemical Gene expression
Protein levels
Receptor binding
Adductformation
especially for biochemical events, there
could be little confidence in the ability of
the model to predict outside the range of
data for more coordinated biological re-
sponses such as cancer. The use ofmodels
in risk assessment thus demands careful
scrutiny of the behavior of the model un-
der a variety of exposure scenarios. This
scrutiny has not generally been applied in
science to the use of mechanistic models.
It is important to note that mechanistic
modeling has a role to aid in explaining
and understanding experimental results,
separate from its use in risk assessment.
Our confidence in the methods used in
mechanistic modelingwill differwith use.
In any modeling exercise, the major
components of the model revolve around
the estimation of model parameters using
statistical tools. These tools range from
simple techniques, such as estimating a
mean, to complicated approaches, such as
estimation via maximizing a statistical like-
lihood. Estimating parameters is tied to
the data available to characterize the
model. The way in which data are used to
obtain estimates ofthe model parameters is
the major component in determining the
confidence placed in any mathematical
model.
In modeling biological phenomena, the
data can be divided into four broad cate-
gories, as shown in Table 2. At the top are
effects on the whole animal. Examples of
data included in this category include sur-
vival of the organism, its ability to repro-
duce, and its ability to properly function.
The levels of data then decrease and
become more specific, going from whole
organism to tisssue/organ system responses
to cellular responses, and finally down to
biochemical responses in the cell. The
data in Table 2 range from very general
(often no more detail than mortality data)
to highly specific mechanistic data dealing
with the interactions between molecules.
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All ofthis information is relevant and must
be incorporated into a mathematical model
aimed at understanding the specific biolog-
ical response.
The goal of mechanistic models gener-
ally applicable to risk asssessment is to pre-
dict outcomes, whether at the organism
level (e.g., survival) or at the tissue level
(e.g., carcinogenicity). In building such a
model, it is the goal ofmechanistic model-
ing to explain most, ifnot all, ofthe avail-
able data. Mathematical models that in-
corporate parameters which are mechanis-
tic in nature do not automatically consti-
tute "mechanistic models." The types of
data available for the model and the meth-
od by which these data are incorporated
into the model determines if a model is
truly "mechanistic": one that is soundly
based on the biology rather than simply fit-
ting a curve to the same data.
There are two basic ways biological
effects can be estimated. The first and
most common approach is a "top-down"
approach. In the top-down approach, data
on the effect ofinterest (e.g., carcinogenic-
ity) is modeled directly by applying statisti-
cal tools to link the observed data (e.g.,
tumor incidence data from a carcinogenici-
ty experiment) to a model (e.g., the multi-
stage model of carcinogenesis). This ap-
proach is extremely powerful in its ability
to describe the observed results and to gen-
erate hypotheses about model parameters
and the potential effects of changes in
these parameters. Where this modeling
approach begins to lack credibility is in its
ability to predict responses outside the
range ofthe data currently being evaluated.
Even when the model being applied to the
data is mechanistic in the sense that the
model parameters are tied to some mecha-
nism for the toxic effect (e.g., mutation
rates and molecular effects), without direct
evidence concerning the value for this
parameter or even evidence supporting the
particular structure of the model, one is
basically left with a curve fit to the data.
The historical application of the LMS in
risk assessment for carcinogens has been
used in this fashion.
True mechanistic modeling must be
viewed differently. In this case, the
model structure and the parameters in
the model are derived in a "bottom-up"
fashion. The mechanistic parameters in
the model are estimated directly from
mechanistic data rather than from effects
data or data one level higher in the hier-
archy of data illustrated in Table 2. The
goal of true mechanistic modeling is to
explain all or most known results relating
to the process under study in a way that
is biologically reasonable and soundly
rooted in the data at hand. In this case,
biological confidence in predictions from
the model would be much higher than
that from the curve-fitting approach.
The major difference between the appli-
cation of a "curve-fit" model in basic
biology and that in risk estimation is that
in basic biology one is creating hypothe-
ses which at some point can be tested. In
risk estimation, it is unlikely that one will
ever be able to validate extrapolated risk
estimates.
In practice, it is difficult to complete-
ly eliminate curve fitting from mechanis-
tic modeling. At some point in the mod-
eling process, gaps must be filled relating
the modeled mechanistic effects to the
observed toxic effects. It is generally at
this point that some amount of curve fit-
ting is necessary to calibrate the mecha-
nistic response to the toxic effect. Al-
though not technically mechanistic mod-
eling, this combined approach is pre-
ferred to simple curve fitting when infer-
ences outside of the range of the toxic
effects data are to be made.
Mechanistic modeling does not
necessarily provide a precise estimate of
risk of a toxic effect outside the range of
the data or even necessarily more precise
or even im-proved estimates of risk than
curve fitting alone. Without data (as in
the case of extrapolation), the statistical
issue of the accuracy of a prediction can-
not be easily addressed. Thus, although
there may be a greater deal of biological
confidence in extrapolated results, it is
unlikely that an increased statistical confi-
dence can be demonstrated. However, for
each level and type of data, there are
ranges of exposure beyond which it is
impossible to dem-onstrate an effect given
the practical constraints on the experimen-
tal protocols. In general, effects can be
demonstrated at lower exposures for more
specific data compared to the more gener-
al data (Table 2). When this is the case,
there may be both increased biological
confidence in extrapolated results and
increased statistical accuracy. This does
not imply that models derived through
curved fitting should always be given less
weight.
Many additional issues are related to
the frequency of the use of the model
development loop in trying to understand
a biological mechanism. One issue ofcon-
siderable importance is experimental de-
sign. For mechanistic modeling aimed at
risk assessment, we are just beginning to
understand the types of experiments that
may benefit the risk estimation process.
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Thus, now is the perfect time to consider
the types ofdesigns best suited to address-
ing problems specific to risk assessment.
In most experimental designs one would
have a mechanism in mind, qualitatively
describe that mechanism, form the struc-
ture ofa mechanistic model, make educat-
ed guesses about the parameters of this
model, and then use the quantitative
model to develop experimental designs that
are optimal at characterizing the mecha-
nism.
For exploring and examining the abili-
ty ofmechanistic modeling to improve the
accuracy of quantitative risk assessment,
TCDD can be considered as a prototype.
The database for a mechanistic modeling
approach to TCDD is extensive and con-
tains a considerable amount ofinformation
on low-dose behavior. In addition, there is
reasonably good concordance between
human data and experimental evidence in
animals. On the other hand, some aspects
of the mechanism by which TCDD in-
duces its effects have not been modeled
extensively, and thus we are in the early
loops through the model development
cycle shown in Figure 5. As a result, sever-
al competing mechanistic theories may
agree with the existing data, adding to the
uncertainty in any projected risk estimates.
This outcome is inevitable for a novel
mechanism and for the application of the
technology of mechanistic modeling to a
new area. As stated earlier, mechanistic
modeling has a role to aid in explaining
and understanding experimental results,
beyond its proposed use in risk assessment.
Our confidence in the methods used in
mechanistic modeling will differ depend-
ing on the history of its use. As we know
more about the limitations ofcurrent data
and current methods for the application of
mechanistic models to risk estimation, we
can improve experimental designs and sig-
nificantly improve the process.
Dioxin is an example ofearly attempts
to develop mechanistic models for risk as-
sessment. Scientists have gained consider-
able insights into the complex network of
events that affect the mechanisms whereby
receptor-mediated events regulate gene
expression and mitotic activity, and the sci-
entific foundation, although far from com-
plete, is sufficient to warrant the develop-
ment of biologically based dose-response
models for the effects ofdioxin. However,
we must be cautious in judging the overall
and immediate utility ofmechanistic mod-
eling in risk assessment based on our expe-
riences with dioxin.
1. Tennant RW, Margolin BR, Shelby MD,
Zeiger E, Haseman JK, Spalding J, Caspary W,
Resnik M, Stasiewicz S, Anderson B, Minor R.
Prediction of chemical carcinogenicity in
rodents from in vitro genetic toxicity assays.
Science 236: 933-941(1987).
2. Swenberg JA, Richardson FC, Boucheron JA,
Deal FH, Belinksy SA, Charbonneau M, Short
BG. High- to low-dose extrapolation: critical
determinants involved in the dose response of
carcinogenic substances. Environ Health Per-
spect 76:57-63(1987).
3. Lucier GW. Receptor-mediated carcinogene-
sis. In: Mechanisms of carcinogenesis in risk
identification (Vainio EH, Magee PN,
McGregor DB, McMichael AJ, eds), IARC
Scientific Publications No. 116. Lyon: Inter-
national Agency for Research on Cancer, 1992;
87-112.
4. Barret JC. Multistage carcinogenesis. In:
Mechanisms ofcarcinogensis in risk identifica-
tion (Vanio H, Magee PN, McGregor DB,
McMichael AJ, eds), IARC Scientific Publica-
tions No. 116. Lyon: International Agency for
Research on Cancer, 1992; 115-134.
5. Butterworth BE, Slaga T, eds. Chemically
induced cell proliferation: implications for risk
assessment. NewYork: Wiley-Liss, 1990.
6. Hoel DG, Haseman JK, Hogan MD, HuffJ,
McConnell EE. The impact oftoxicity on car-
cinogenicity studies: implications for risk as-
sessment. Carcinogenesis 9: 1935-1941(1988).
7. Ames BN, Gold LS. Too many rodent car-
cinogens: mitogenesis increases mutagenesis.
Science 249:270(1990).
8. Zeise L, Huff JE, Salmon AG, Hooper NK
Human risks from 2,3,7,8-tetrachlorodibenzo-
p-dioxin and hexachlorodibenzo-p-dioxins.
Adv Mod Environ Toxicol 17:293-342
(1990).
9. Roberts L. EPA moves to reassess the risk of
dioxin. Science 252:9-11 (1991).
10. Roberts L. More pieces in the dioxin puzzle.
Science 254:377(1991).
11. Goldstein JA, Safe S. Mechanism of action
and structure-activity relationships for the
chlorinated dibenzo-p-dioxins and related com-
pounds. In: Halogenated biphenyls, ter-
phenyls, naphthalenes, dibenzodioxins, and
related products (Kimbrough RD, Jensen AA,
eds). New York:Elsevier, 1989; 239-293.
12. Schlatter C. Data on kinetics of PCDDs and
PCDFs as a prerequisite for human risk assess-
ment. In: Biological basis for risk assessments
of dioxins and related compounds (Gallo M,
Scheuplein R, Van der Heijden K, eds), Ban-
bury Report 35. Cold Spring Harbor, New
York:Cold Spring Harbor Laboratory Press,
1991; 215-228.
13. Vickers AEM, Sloop TC, Lucier GW. Mech-
anism ofaction oftoxic halogenated aromatics.
Environ Health Perspect 59:121-128(1985).
14. Kociba RJ, Keyes DG, Beyer JE, Carreon RM,
Wade CE, Dittenber DA, Kalnins RP, Frauson
LE, Park CN, Barnard SD, Hummel RA,
Humiston CG. Results of a two year chronic
toxicity and oncogenicity study of 2,3,7,8-
tetrachlorodibenzo-p-dioxin in rats. Toxicol
Appl Pharmacol 46:279-303.
15. HuffJE, Salmon AG, Hooper NK, Zeise L.
Long-term carcinogenesis studies on 2,3,7,8-
tetrachlorodibenzo-p-dioxin and hexachloro-
dibenzo-p-dioxins. Cell Biol Toxicol 7:
67-94(1991).
16. Shu HP, Paustenbach DJ, Murray FJA. A
crititcal evaluation of the use of mutagenesis,
carcinogenesis and tumor promotion data in a
cancer risk assessment of 2,3,7,8-tetrachloro-
dibenzo-p-dioxin. Regul Toxicol Pharmacol
7:57-58(1987).
17. Yang J, Thraves P, Dritschilo A, Rhim JS.
Neoplastic transformation of immortalized
human keratinocytes by 2,3,7,8-tetra-
chlorodibenzo-p-dioxin. Cancer Res 52:
3478-3482(1992).
18. Pitot HC, Goldsworthy TL, Campbell HA,
Poland A. Quantitative evaluation ofthe pro-
motion by 2,3,7,8-tetrachlorodibenzo-p-dioxin
of hepatocarcinogenesis from diethylni-
trosamine. Cancer Res 40:3616-3620 (1980).
19. Lucier GW, Tritscher AM, Goldsworthy T,
Foley J, Clark G, Goldstein J, Maronpot R.
Ovarian hormones enhance TCDD-mediated
increases in cell proliferation and preneoplastic
foci in a two stage model for hepatocarcinogen-
esis. Cancer Res 51:1391-1397(1991).
20. Dragan YP, Xu X, Goldsworthy TL, Campbell
HA, Maronpot RR, Pitot HC. Characteriza-
tion ofthe promotion ofaltered hepatic foci by
2,3,7,8-tetrachlorodibenzo-p-dioxin in female
rats. Carcinogenesis 13:1389-1395 (1992).
21. Fingerhut MA, Halperin WE, Marlow DA,
Piacitelli LA, Honchar PA, Sweeney ME,
Greife AL, Dill PA, Steenland K, Suruda AH.
Cancer mortality in workers exposed to
2,3,7,8-tetrachlorodibenzo-p-dioxin. N Engl J
Med 324:212-218(1991).
22. Birnbaum L. Evidence for the role of the Ah
receptor in responses to dioxin. Prog Clin Biol
Res (in press).
23. Silbergeld EK, Gasiewicz TA. Dioxins and the
Ah receptor. Am J Ind Med 16: 455-474
(1989).
24. Sutter TR, Guzman K, Dold KM, Greenlee
WF. Targets for dioxin: genes for plasminogen
activator inhibitor-2 and interleukin-lb.
Science 254:415-417(1991).
25. Clark G, Tritscher A, Maronpot R, Foley J,
and Lucier G. Tumor promotion by TCDD
in female rats. In: Biological basis for risk
assessment of dioxin and related compounds
(Gallo M, Scheuplein R, Van der Heijden K,
eds), Banbury Report 35. Cold Spring
Harbor, New York:Cold Spring Harbor Lab-
oratory Press, 1991;389-404.
26. Poland A, Glover E, Kende AS. Stereospecific,
high affinity binding of 2,3,7,8-tetrachloro-
dibenzo-p-dioxin by hepatic cytosol. Evidence
that the binding species is the receptor for
induction of aryl hydrocarbon hydroxylase. J
Biol Chem 251:4936(1976).
27. WhitlockJP Jr. Genetic and molecular aspects
of 2,3,7,8-tetrachlorodibenzo-p-dioxin action.
Annu Rev Pharmacol Toxicol 30: 251-277
(1990).
28. Gasiewicz TA, Elferink CJ, Henry EC.
Characterization of multiple forms of the Ah
receptor: recognition of a dioxin-response
enhancer involves heteromer formation.
Biochemistry 30:2909(1991).
29. Burbach KM, Poland A, Bradfield CA.
Cloning ofthe Ah receptor cDNA reveals a dis-
tinctive ligand-activated transcription factor.
Proc NatlAcad Sci USA 89: 8185-8189(1992).
30. Ema M, Sogawa K, Watanabe N, Chujoh Y,
Matsushita N, Gotoh 0, Fumae Y, Fujii-
Kuriyama Y. cDNA cloning and structure of
mouse putative Ah receptor. Biochem Bio-
phys Res Commun 184: 246-253(1992).
31. Hoffman EC, Reyes H, Fong-Fong C. Clon-
ing of a factor required for activity of the Ah
(dioxin) receptor. Science 252: 954(1991).
32. Wu L, Whitlock P Jr. Mechanism of dioxin
action: receptor-enhancer. Nucleic Acids Res
21:119-125(1993).
33. Perdew GH. Association of the Ah receptor
with the 90-kDa heat shock protein. J Biol
Chem 263:13802-13805(1988).
Volume 101, Number 1, April22, 1993 43...- E'
A.
34. Roth J, Grunfeld C. Mechanism of action of
peptide hormones and catecholamines. In:
Textbook ofendocrinology (Wilson JD, Foster
DW, eds). Philadelphia: WB Saunders,
1985;76- 122.
35. Tritscher AM, Goldstein JA, Portier CJ,
McCoy Z, Clark GC, Lucier GW. Dose-
response relationships for chronic exposure to
2,3,7,8-tetrachlorodibenzo-p-dioxin in a rat
tumor promotion model: quantification and
immunolocalization of CYPlAI and CYP1A2
in the liver. Cancer Res 52:3436-3442
(1992).
36. Portier C, Tritscher A, Kohn M, Sewall C,
Clark G, Edler L, Hoel D, Lucier G. Ligand/
receptor binding for 2,3,7,8-TCDD: Impli-
cations for risk assessment. Fundam AppI
Toxicol 20:48-56(1993).
37. Kohn MC, Lucier GW, Portier CJ. A mecha-
nistic model of effects of dioxin on gene ex-
pression in the rat liver. Toxicol Appl
Pharmacol (in press).
38. Anderson ME, Mills J, Kedderis L, Neubert D,
Greenlee W. Modeling receptor mediated
processes with dioxin implications for pharma-
cokinetics and risk assessment. Risk Anal (in
press).
39. Fuller P. The steroid receptor superfamily:
mechanisms of diversity. FASEB J 5:3092-
3099(1991).
40. Poland A, Palen D, Glover E. Tumor promo-
tion by TCDD in skin ofHRS/J mice. Nature
300:271-273(1982).
41. U.S. EPA. Health assessment document for
polychlorinated dibenzo-p-dioxins. Document
EPA/600/8-84-014F. Cincinnati, Ohio: Office
ofHealth and Environmental Assessment, U. S.
Environmental Protection Agency.
42. Hoel D. Incorporation of background in
dose- response models. Fed Proc 39: 73-75
(1980).
43. Portier C. Statistical properties of a two-stage
model of carcinogenesis. Environ Health
Perspect 76:125-132(1987).
44. Greenlee WF, Anderson ME, Lucier GW. A
perspective on biologically based approaches to
dioxin risk assessment. Risk Anal 11:565-
568(1991).
45. Needham LL. Levels of TCDD in selected
human populations. In: Biological basis for
risk assessment of dioxin and related com-
pounds (Gallo M, Scheuplein R, van der
Heijden C, eds), Banbury Report 35. Cold
Spring Harbor, New York:Cold Spring Harbor
Laboratory Press, 1991;229-291.
46. Lucier GW. Humans are a sensitive species to
some of the biochemical effects of structural
analogs of dioxin. Environ Toxicol Chem
10:727-735(1991).
47. Clark G, Tritscher A, Bell D, Lucier G.
Integrated approach for evaluating species and
interindividual differences in responsiveness to
dioxins and structural analogs. Environ Health
Perspect 98:125-132(1992).
48. Anthony-Cahill S, Benfield P, Fairman R,
Wasserman Z, Brenner S, Stafford W III,
Altenbach C , Hubbell W, Degrado W. Mo-
lecular Characterization of helix-loop-helix
peptides. Science 255:979-983 (1992).
European Organization U.S. National
for Research and Cancer
Treatment of Cancer Institute
The European Organization for Research and Treatment of Cancer (EORTC) and the U.S. Nation-
al Cancer Institute (NCI) are offering an exchange program to enable cancer researchers to work
at NCI or EORTC-related institutions for one to three years.
General Conditions Documentation European sources. Non-EORTC
Awardees will receive an annual sub- The following documents are member country candidates must con-
sistence allowance of$30,000. Halfof required, in English, from all tinue at full salary at the home institu-
this amount will be provided by U.S. applicants: tion for the duration of the exchange-
sources, the remainder by European * Completed application form. ship.
sources. * Description of the research to be * Three letters ofrecommendation
European awardees will receive the undertaken, not to exceed three type- mailed directly to the NCI Liaison
U.S. contribution either from the NCI written pages. Office by the recommending
or from their extramural host institu- * Letter of invitation from the individuals.
tion. The European contribution of prospective host. For More Information Contact:
the exchangeship will be provided . Agreement to release the applicant EORTC/NCI Exchange Program
either by the scientist's home institu- from the home institution for the NCI Liaison Office
tion orby a European granting duration of the exchangeship. 83, Avenue E. Mounier
agency. * Assurance of intention to return to 1200 Brussels, Belgium
For American awardees, the host the home institution at the end of the Telephone: (32) (2) 772-22-17
institution must be affiliated with the exchangeship. Telefax: (32) (2) 770-47-54
EORTC. * Statement concerning the provision
of50 percent of financial support by
44 Environmental Health Perspectives